In this review, we are going to look at the Zomedica stock forecast. The thing is that more and more people are looking for companies to invest in, and they want the most beneficial options. That is why it is crucial to figure out as much as possible about a stock before buying shares.
But what is it? Zomedica happens to be a veterinary health organization that develops goods for companion animals (feline, canine, and equine). They are concerned about clinical veterinarians` demand, and their product portfolio comprises therapeutics and diagnostics that highlight practice and patient health. The organization is working on the final development of their platform – Truforma, at the moment. The goal is to make it possible to detect thyroid disorders in cats and dogs as well as adrenal disorders in dogs.
So, let`s find out whether this company is going to be a worthy investment.
ZOM Stock Prediction
Zomedica seems to be a tiny vet-med stock, which has recently become one of the biggest winners on Wall Street. The reason is that the company has managed to rise by more than a thousand percent since November. But, let`s see what Zomedica stock predictions for the nearest future are.
Zomedica Stock Predictions 2021
Right now, the share costs 0.658 dollars, which is an increase. However, analytics believe that the price will fall by 9.42 percent in September and will keep decreasing until the end of the year. So, the Zomedica stock predictions 2021 are somewhat pessimistic because the share will cost approximately 0.518 dollars.
ZOM Stock Forecast 2022
According to the ZOM forecast for the next year is a bit more optimistic because it will grow by 16.88 percent and make up 0.524 dollars per share in January 2022. They also expect it to increase even more and reach a maximum of 0.7 dollars in February. However, the stock price is going to fluctuate thought the year, causing major ups and downs. It will all end up in a dramatic fall, so the stock will cost only 0.2 dollars in December 2022.
ZOM Stock Forecast 2025
Interestingly, Zomedica stock predictions look more positive if stretched to 2025, which makes this stock a great long-term investment. It is trading below 0.90 dollars at the moment, while the market capitalization is 825 million dollars. The cash burn in the first quarter is unknown, so the total cash can be approximately 250 million dollars. It implies that the enterprise value should be 575 million dollars.
As mentioned before, the company is commercializing Truforma that is a point-of-care device. It is supposed to be used by veterinary doctors. This platform should help the company grow and increase its income. Therefore, the ZOM stock forecast is that it will rise to 5 billion dollars by 2024 compared to 1.7 billion dollars in 2019. It implies that the price can reach 1.68 dollars in 2025.
ZOM Stock: Buy or Sell?
In the short term, the ZOM price target may be susceptible to decrease. Even though the stock might be getting near its bottom right now, it can turn out to be a winner. This scenario is possible if you are patient and are able to hold the stock for a long period of time.
The balance sheet of the medical company appears to be strong, and it obtains more money than required. Furthermore, they believe that there will be some acquisitions, which should result in the stock price rise.
To sum it up, Zomedica can be a good buy from the long-term point of view.
Due to a generally good trend, the short-term signal is positive; consequently, it is possible to conclude that the company is worth being considered as an investment. The thing is that the company has great potential, and it keeps developing.
According to the SWOT analysis, Zomedica is loss-making now, but it obtains exclusive distribution agreements. Thus, the company is predicted to be profitable in the following three years due to Truforma. At the same time, there can be more projects because ZOM has enough money to invest. Since the ZOM price prediction is positive, it is recommended to use it as a long-term investment.
Ethan Moore, crypto and stock trader since 2012. Co-founder of Blockwatch experts team.